Live Breaking News & Updates on Michaela Klufas

Stay updated with breaking news from Michaela klufas. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Building Confidence in Biosimilars in Ophthalmology

Rishi P. Singh, MD; and Michael A. Klufas, MD, discuss how to gain both physician and patient trust when it comes to using biosimilars to treat ophthalmologic conditions. ....

Michaela Klufas , Biosimilars With Treatment , Retina Vascular Disease , Wet Amd , Age Related Macular Degeneration , Don Label , Peer To ,

Biosimilars in Ophthalmology: Challenges, Access, and Patient Assistance Programs

Retina specialists review the current challenges with biosimilars in ophthalmology, commenting on insurance coverage and patient assistance programs. ....

United States , Michaela Klufas , Wet Amd , Age Related Macular Edema , Insurance Coverage ,

Rationale for Shorter Endpoints in Biosimilar Clinical Trials

Rishi P. Singh, MD; and Michael A. Klufas, MD, comment on the reasoning behind a shorter primary end point for biosimilar studies. ....

Michaela Klufas , Wet Amd , Age Related Macular Edema , Short Primary Endpoint , Anti Vegf ,

Current Anti-VEGF Biosimilars Approved for Ophthalmologic Conditions

Rishi P. Singh, MD; and Michael A. Klufas, MD, provide an overview of the 2 currently available ophthalmology biosimilars, ranibizumab-eqrn and ranibizumab-nuna, as well as discuss which patient populations will benefit from these treatments. ....

Michaela Klufas , Wet Amd , Age Related Macular Edema , Ranibizumab Nuna , Ranibizumab Eqrn ,

Challenges With Off-Label Bevacizumab Use in Retinal Diseases

Michael A. Klufas, MD, discusses issues with off-label bevacizumab use, focusing on compounding issues and decreases in clinical efficacy due to repackaging. ....

Michaela Klufas , Szilard Kiss , Pine Pharmacies , Wet Amd , Age Related Macular Edema , Off Label Bevacizumab , Compounded Medications , Reduced Clinical Efficacy ,